可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Cohn JN, Tognoni G. Valsartan heart failure trial investigators. A randomized trial of angiotensinreceptor blocker valsartan in chronic heart failure [J]. N Engl J Med, 2001, 345(23):1667-1675.
[2] McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensinconvertingenzyme inhibitors: the CHARMAdded trial[J].Lancet. 2003,362(9379):767-771.
[3] Solomon SD,Wang D,Finn P,et al.Effect of candesartan on causespectific mortality in heart failure patients :the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM)program.[J].Circulation,2004,110 (15): 2180-2183 .
[4] 郭明,王亚,郭沫化,等.比较伊贝沙坦与培哚普利对充血性心力衰竭患者细胞因子和血管辖紧张素Ⅱ的影响[J].心脏杂志,2005,17(1):52-57.
[5] Pfeffer MA,McMurray JJ,Velazquez EJ,et al.Valsartan,captopril,or both in myocardial infarction complicated by heart failure,left ventricular dysfunction,or both[J].N Engl J Med,2003,349 (20) :1893-1906.
[6] Mann DL,Deswal A.Angiotensinreceptor blockade in acute myocardial infarctiona matter of dose[J].N Engl J Med,2003,340(20):1963-1965.
[7] Antman EM,Anbe DT,Armstrong PW, et al. ACC/AHA guidelines for the management of patients with STelevation myocardial infarctionexecutive summary : a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines(Uriting Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction)[J].Circulation , 2004,110 (5) : 588-636.